Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04175210 · ClinicalTrials.gov registry record · Phase 3
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
A Phase 3 study of Breast Cancer, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 3
- Study locations
NCT04175210 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 400 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT04175210, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experimental).
Conditions Studied
Interventions
- RADIATION Radiation therapy - 2 weeks
- RADIATION Radiation therapy - 3 weeks
Study Locations (3)
New York
- New York Presbyterian Hospital at Lower Manhattan Cancer Center - New York
- Brooklyn Methodist Hospital - NewYork Presbyterian - New York
- New York Presbyterian Hospital - Queens - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2019-11-21 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04175210
The ClinicalTrials.gov registry entry for NCT04175210 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation therapy - 2 weeks is the first listed.
NCT04175210 reports 3 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04175210 about?
NCT04175210 is a clinical study titled "Prospective Randomized Study of Accelerated Radiation Therapy (PRART)". Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experimental).
What is the current status of trial NCT04175210?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2019-11-21. Estimated completion is 2030-06-30.
What conditions does trial NCT04175210 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04175210?
The interventions under investigation include: Radiation therapy - 2 weeks (RADIATION), Radiation therapy - 3 weeks (RADIATION).
Who is sponsoring clinical trial NCT04175210?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04175210 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.